The U.S. Food and Drug Administration has provided an update on the supply of lower doses of Novo Nordisk's Wegovy 

Initially, there were estimates of resuming supply this month, but now the FDA states that it's unclear when the supply will normalize 

The FDA has listed the 0.25 mg, 0.5 mg, and 1 mg doses of Wegovy as having limited availability 

The duration of the shortage for these lower doses has not been determined 

However, the larger doses of 1.7 mg and 2.4 mg are still available for patients 

Novo Nordisk's CEO, Lars Fruergaard Jorgense, mentioned that limits on U.S. supplies of starter doses of Wegovy will continue into the next year 

Despite the shortage, Novo Nordisk is investing billions to increase production to meet the high demand for the drug 

Wegovy was approved by the FDA in 2021 for chronic weight management 

It is specifically intended for people with obesity 

Patients and healthcare providers will need to monitor the situation closely due to the uncertainty surrounding the supply of lower Wegovy doses